[HTML][HTML] Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients
E Deutsch, C Haie-Meder, MA Bayar, M Mondini… - Oncotarget, 2016 - ncbi.nlm.nih.gov
E Deutsch, C Haie-Meder, MA Bayar, M Mondini, M Laporte, R Mazeron, J Adam, A Varga…
Oncotarget, 2016•ncbi.nlm.nih.govPhase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in
cervical cancer patients - PMC Back to Top Skip to main content NIH NLM Logo Access keys
NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List Oncotarget v.7(18); 2016
May 3 PMC5041925 Other Formats PDF (1.7M) Actions Cite Collections Share Permalink Copy
RESOURCES Similar articles Cited by other articles Links to NCBI Databases Journal List …
cervical cancer patients - PMC Back to Top Skip to main content NIH NLM Logo Access keys
NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List Oncotarget v.7(18); 2016
May 3 PMC5041925 Other Formats PDF (1.7M) Actions Cite Collections Share Permalink Copy
RESOURCES Similar articles Cited by other articles Links to NCBI Databases Journal List …
Abstract
Purpose
This phase I trial aimed to assess the safety and determine the recommended Phase II dose (RP2D) of Cidofovir combined with chemoradiotherapy in patients with stage IB2-IVA cervical cancer.
ncbi.nlm.nih.gov